赛托生物
(300583)
| 流通市值：46.00亿 | | | 总市值：46.88亿 |
| 流通股本：1.86亿 | | | 总股本：1.90亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 148,445,436.47 | 258,727,186.35 | 351,284,155.1 | 238,490,756.82 |
| 应收票据及应收账款 | 226,439,613.49 | 304,015,815.01 | 271,654,095 | 272,117,151.74 |
| 应收账款 | 226,439,613.49 | 304,015,815.01 | 271,654,095 | 272,117,151.74 |
| 应收款项融资 | 211,751,912.67 | 197,685,245.86 | 146,032,897.43 | 111,080,353.54 |
| 预付款项 | 27,214,522.94 | 18,065,397.44 | 7,217,645.98 | 5,367,236.48 |
| 其他应收款合计 | 16,847,378 | 19,649,711.47 | 24,400,751.55 | 22,731,965.72 |
| 存货 | 690,194,330.29 | 682,750,304.39 | 730,067,778.48 | 722,624,129.92 |
| 其他流动资产 | 23,726,974.01 | 21,603,184.21 | 21,748,620.43 | 25,375,111.39 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,344,620,167.87 | 1,502,496,844.73 | 1,552,405,943.97 | 1,397,786,705.61 |
| 非流动资产: | | | | |
| 长期股权投资 | 69,490,845.46 | 68,292,565.69 | 67,022,673.3 | 65,119,540.6 |
| 固定资产 | 1,119,845,035.9 | 1,140,022,109.81 | 1,227,569,958.97 | 1,266,998,561.61 |
| 在建工程 | 344,091,869.77 | 310,905,223.34 | 300,171,159.41 | 279,287,721.36 |
| 使用权资产 | 4,822,888.07 | 7,569,902.78 | 8,924,749.91 | 9,627,309.04 |
| 无形资产 | 190,291,235.89 | 192,141,729.5 | 197,459,899.44 | 200,581,837.81 |
| 长期待摊费用 | 914,598.48 | 1,043,259.63 | 1,171,920.78 | 1,300,581.93 |
| 递延所得税资产 | 7,901,496.86 | 7,673,939.84 | 6,858,885.63 | 11,265,195.76 |
| 其他非流动资产 | 5,171,496.68 | 5,269,029.44 | 8,502,227.38 | 8,274,950.12 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,742,529,467.11 | 1,732,917,760.03 | 1,817,681,474.82 | 1,842,455,698.23 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,087,149,634.98 | 3,235,414,604.76 | 3,370,087,418.79 | 3,240,242,403.84 |
| 流动负债: | | | | |
| 短期借款 | 618,426,438.25 | 656,358,357.56 | 761,781,519.39 | 627,006,377.49 |
| 应付票据及应付账款 | 293,393,765.79 | 304,898,369.06 | 293,969,203.86 | 246,821,029.54 |
| 其中：应付票据 | 159,523,971.7 | 139,373,098.69 | 98,488,853.06 | 54,209,766.03 |
| 应付账款 | 133,869,794.09 | 165,525,270.37 | 195,480,350.8 | 192,611,263.51 |
| 合同负债 | 5,308,999.12 | 5,259,248.56 | 5,616,773.46 | 5,577,858.63 |
| 应付职工薪酬 | 8,868,254.27 | 8,691,447.33 | 20,504,655.85 | 22,306,901.88 |
| 应交税费 | 12,897,214.91 | 12,721,894.97 | 12,292,200.63 | 16,121,790.4 |
| 其他应付款合计 | 16,471,765.67 | 102,620,916.37 | 30,382,321.05 | 19,536,474.35 |
| 应付股利 | - | 85,365,956.7 | - | - |
| 一年内到期的非流动负债 | 19,047,937.43 | 19,135,046.91 | 27,395,954.89 | 48,979,778.5 |
| 其他流动负债 | 474,871.48 | 128,179.13 | 301,840.46 | 409,081.08 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 974,889,246.92 | 1,109,813,459.89 | 1,152,244,469.59 | 986,759,291.87 |
| 非流动负债: | | | | |
| 长期借款 | 51,862,836 | 57,436,000.73 | 72,817,119.34 | 108,340,829.15 |
| 租赁负债 | 3,002,861.42 | 6,366,700.75 | 6,948,546.77 | 7,256,437.32 |
| 长期应付款 | 35,909,979.28 | 39,703,157.42 | 43,459,151.22 | 47,123,081.78 |
| 递延收益 | 22,130,912.1 | 22,936,441.7 | 23,741,971.3 | 24,547,500.9 |
| 递延所得税负债 | 659,924.25 | 694,677.8 | 731,684.63 | 768,691.61 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 113,566,513.05 | 127,136,978.4 | 147,698,473.26 | 188,036,540.76 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,088,455,759.97 | 1,236,950,438.29 | 1,299,942,942.85 | 1,174,795,832.63 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 189,702,126 | 189,702,126 | 189,702,126 | 189,702,126 |
| 资本公积 | 1,276,956,870.47 | 1,276,956,870.47 | 1,276,956,870.47 | 1,276,956,870.47 |
| 其他综合收益 | - | - | -205,389.28 | -1,097,419.76 |
| 盈余公积 | 93,766,209.97 | 93,766,209.97 | 93,766,209.97 | 93,766,209.97 |
| 未分配利润 | 382,178,378.18 | 380,674,422.91 | 455,899,751.21 | 452,829,022.56 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,942,603,584.62 | 1,941,099,629.35 | 2,016,119,568.37 | 2,012,156,809.24 |
| 少数股东权益 | 56,090,290.39 | 57,364,537.12 | 54,024,907.57 | 53,289,761.97 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,998,693,875.01 | 1,998,464,166.47 | 2,070,144,475.94 | 2,065,446,571.21 |
| 负债和股东权益合计 | 3,087,149,634.98 | 3,235,414,604.76 | 3,370,087,418.79 | 3,240,242,403.84 |
| 公告日期 | 2024-10-29 | 2024-08-27 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |